This trial will study if CAR-T cells can be used to treat cHL, and if they can be combined with PD-1 antibodies to improve clinical responses.
1 Primary · 3 Secondary · Reporting Duration: From first day of anti-PD-1 therapy to clinical progression or death, up to 15 years
20 Total Participants · 3 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase < 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: